|
|
POLYDEX PHARMACEUTICALS ISSUES THIRD QUARTER FINANCIAL REPORT |
|
|
POLYDEX REPORTS SECOND QUARTER
FINANCIAL RESULTS |
|
|
POLYDEX REPORTS RECEIVING NASDAQ
HEARINGS PANEL DECISION |
|
|
POLYDEX ANNOUNCES FINAL REPORT
FROM PHASE III STUDY OF USHERCELL |
|
|
POLYDEX PHARMACEUTICALS TO APPEAL
STAFF DETERMINATION LETTER FROM NASDAQ |
|
|
POLYDEX ISSUES BUSINESS OUTLOOK REPORT |
|
|
POLYDEX BUSINESS OUTLOOK REPORT 2008.PDF |
|
|
POLYDEX REPORTS FIRST QUARTER FINANCIAL RESULTS SHAREHOLDER EQUITY OF COMPANY EXCEEDS CURRENT SHARE PRICE |
|
|
POLYDEX PHARMACEUTICALS LIMITED – 2008 FISCAL YEAR END RESULTS GROWTH OF CORE PRODUCT SALES A PRIORITY FOR FISCAL 2009 |
|
|
POLYDEX ANNOUNCES USHERCELL PREVENTS SYSTEMIC SHIV INFECTION IN RHESUS MACAQUES IN NEW CLINICAL TRIAL |
|
|
POLYDEX PHARMACEUTICALS RECEIVES
STAFF DEFICIENCY LETTER FROM NASDAQ |
| |
|
|
| |
|
|
